04:32 AM EST, 01/13/2025 (MT Newswires) -- Teva Pharmaceutical Industries' ( TEVA ) Teva Pharmaceuticals International subsidiary said Monday it has entered into a collaboration with Klinge Biopharma and Formycon for the semi-exclusive commercialization of FYB203, Formycon's biosimilar candidate to Eylea, in Israel and Europe, excluding Italy.

Financial terms were not disclosed.

Klinge has licensed the exclusive global commercialization rights for FYB203, intended to treat eye diseases, from Formycon, the company said.

Under the terms of the collaboration, Teva will lead the commercialization of FYB203 in designated regions under the brand name Ahzantive, while Klinge will receive milestone payments and a portion of product revenue, the company said.